drugset / Trial / NCT06061536
Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.
Phase 2
Completed
64 enrolled
Shanxi Kangbao Biological Product Co., Ltd.
Institute of Pathogen Biology, Beijing, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment before.
Timeline
- Start
- 2023-11-02
- Primary completion
- 2024-11-29
- Completion
- 2025-01-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DTG | Unknown | — | — |
| Subject | Lipovirtide | Unknown | 10 mg | — |
| Subject | Lipovirtide | Unknown | 40 mg | — |
| Subject | Lipovirtide | Unknown | 60 mg | — |
| Background | Lamivudine | Other / unclassified | — | — |
| Background | TDF | Unknown | — | — |